中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

37 records (took 0.036 seconds)

    PULVERULENT PHYTOSTEROL FORMULATIONS
    3.
    发明申请
    PULVERULENT PHYTOSTEROL FORMULATIONS 审中-公开
    粉植物甾醇配方

    公开(公告)号：WO2005009144A8

    公开(公告)日：2005-06-16

    申请号：PCT/EP0312557

    申请日：2003-11-11

    Applicant: BASF AG ,  AUWETER HELMUT ,  BOHN HERIBERT ,  HASSELWANDER OLIVER ,  RUNGE FRANK

    Inventor： AUWETER HELMUT ,  BOHN HERIBERT ,  HASSELWANDER OLIVER ,  RUNGE FRANK

    IPC: A23K1/00 ,  A23K1/16 ,  A23L1/30 ,  A61K8/02 ,  A61K8/63 ,  A61K31/575 ,  A61Q1/00 ,  A61Q19/00 ,  A23K1/165

    CPC classification number: A61K8/02 ,  A23K20/158 ,  A23K20/174 ,  A23K40/10 ,  A23L33/11 ,  A23V2002/00 ,  A61K8/63 ,  A61K31/575 ,  A61Q1/00 ,  A61Q19/00 ,  A23V2250/2136 ,  A23V2250/5072 ,  A23V2250/54246 ,  A23V2250/5028

    Abstract: The invention relates to pulverulent phytosterol formulations, methods for the production and use thereof. The aim of said invention is to deliver the phytosterol formulations incorporatable in aqueous and oily preparations. For this purpose, said pulverulent phytosterol formulations contain at least one type of phytosterol whose mean particle size ranges from 0.01 and 100 mu m, preferably from 0.01 to 10 mu m, better from 0.01 and 2 mu m and ideally from 0.05 and 1 mu m. Said phytosterol formulations are characterised, in particular in that at least one type of phytosterol is used in a semi-amorphous form. In a preferred embodiment, said phytosterol formulations are characterised in that said phytosterol is embedded in a protective colloid matrix.

    Abstract translation: 本发明涉及一种粉状植物甾醇制剂，它们的制备方法和它们的用途。 这是本发明的一个目的是提供一种含有植物固醇制剂，其既可以在水性和油性制剂掺入。 根据本发明这个目的已经通过包括具有在0.01至100微米范围内的平均粒径的至少一种植物甾醇，优选在0.01至2微米的范围内，最优选在0.05〜1的范围微米粉末状植物甾醇制剂实现 ， 本发明的植物甾醇制剂包括 特征还在于，至少一种植物甾醇的存在部分无定形的形式。 植物甾醇制剂的另一优选实施例的特征在于，所述植物甾醇被嵌入在保护性胶体基质。

    USE OF STABLE AMMONIUM LIPONATE SALTS FOR THE TREATMENT OF DIABETIC AND OTHER DISORDERS
    5.
    发明申请
    USE OF STABLE AMMONIUM LIPONATE SALTS FOR THE TREATMENT OF DIABETIC AND OTHER DISORDERS 审中-公开
    硫辛酸稳定铵盐治疗糖尿病和其他疾病USE

    公开(公告)号：WO2006042728A2

    公开(公告)日：2006-04-27

    申请号：PCT/EP2005011147

    申请日：2005-10-17

    Applicant: BASF AG ,  KRAEMER KLAUS ,  HAUNERT FRANK ,  MATUSCHECK MARKUS ,  HASSELWANDER OLIVER ,  KLATT MARTIN JOCHEN

    Inventor： KRAEMER KLAUS ,  HAUNERT FRANK ,  MATUSCHECK MARKUS ,  HASSELWANDER OLIVER ,  KLATT MARTIN JOCHEN

    IPC: A61K31/44 ,  A61P1/18

    CPC classification number: A61K31/44

    Abstract: The invention relates to the use of stable ammonium a-liponate salts for the treatment of a series of disease states, in particular, diabetic disorders and disorders of diabetic origin. The salts (Lp) (A) are formed from a-liponic acid (Lp) and ammonium compounds (A) of general formula (II) or (III). Further application of the salts are related to the treatment of cardiovascular disorders, neurodegenerative disorders and diseases related to chronic kidney failure and/or dialysis treatment, retinopathies, nephropathies, proteinurias, hyperlipidaemias, hypertriglyceridaemias, hypercholesterinaemias, proliferations of smooth muscle cells in arteries, collagenoses, arthritis, fibromyalgias, kidney stones, inflammation, cancer, amyloidoses, osteoporoses, excess weight and obesity, HIV infections and AIDS, metabolic syndrome, oxidative stress and related diseases and the aging process.

    Abstract translation: 本发明涉及使用aLiponsäure的稳定铵盐用于治疗多种疾病状态，包括，特别是糖尿病病症和病症包括糖尿病原点。 盐（LP）（A）是由α-硫辛酸（LP）和通式（II）或（III）形成通式的氨基化合物（A）的。 盐的其它用途是在特定心血管疾病，神经变性疾病和慢性肾功能衰竭和/或透析治疗相关的疾病的治疗; 视网膜病，肾病，蛋白尿，高脂血症，高甘油三酯血症，高胆固醇血症，动脉的平滑肌细胞，结缔组织疾病，关节炎，纤维肌痛，肾结石，炎症，癌症，淀粉样变性，骨质疏松症，肥胖和肥胖，HIV感染和AIDS的增殖; 代谢综合征; 氧化应激和相关疾病; 并通过老化过程定向。

    COMBINATION OF LIPOIC ACIDS AND CONJUGATED ACIDS FOR TREATING DIABETIC DISORDERS
    6.
    发明申请
    COMBINATION OF LIPOIC ACIDS AND CONJUGATED ACIDS FOR TREATING DIABETIC DISORDERS 审中-公开
    作者硫辛酸组合conjuenic治疗糖尿病病症

    公开(公告)号：WO0222111A2

    公开(公告)日：2002-03-21

    申请号：PCT/EP0110501

    申请日：2001-09-11

    Applicant: BASF AG ,  HASSELWANDER OLIVER ,  KRAEMER KLAUS ,  BALDENIUS KAI UWE ,  KLATT MARTIN JOCHEN ,  SCHWEIKERT LONI

    Inventor： HASSELWANDER OLIVER ,  KRAEMER KLAUS ,  BALDENIUS KAI-UWE ,  KLATT MARTIN JOCHEN ,  SCHWEIKERT LONI

    IPC: A61K31/381 ,  A23L1/30 ,  A61K31/00 ,  A61K31/202 ,  A61K31/385 ,  A61P3/10 ,  A61P9/10 ,  A61P13/12 ,  A61P25/02 ,  A61P27/02

    CPC classification number: A61K31/385 ,  A61K31/20 ,  A61K2300/00

    Abstract: The invention relates to the use of lipoic acids, or a physiologically acceptable derivative or salt thereof, and a compound of formula (I): H3C-(CH2)n1-(CH=CH)n3-(CH2)n2-COOH - wherein n1 and n2 independently have the value of a whole number from 3 to 9, n3 has the value of a whole number from 2 to 6, and the number of carbon atoms amounts to 18, 20 or 22 - or a physiologically acceptable derivative or salt thereof, as food supplements, in functional foods and for therapeutic purposes in the treatment of diabetic disorders. The invention also relates to agents having a corresponding active ingredient combination and to agents in the form of commercial packs having corresponding combination preparations or monopreparations for combined use.

    Abstract translation: 本发明涉及使用硫辛酸，生理学上可接受的衍生物或其盐，和式（I）的化合物：H 3 C-（CH 2）N1（CH = CH）N3（CH 2）N2-COOH，式中，n1， N2彼此独立地具有整数的3至9的值的，N3具有从2的整数的至6的值，并且是在功能的18，20或22，生理学上可接受的衍生物或其盐，膳食补充剂，碳原子数 食品（功能性食品）和糖尿病病症的治疗治疗目的。 还描述了装置与相应的活性成分组合物和组合物与相应的组合产品或单一成分的产品组合使用的商业包装的形式。

    10.
    发明专利
    未知

    公开(公告)号：DE50103029D1

    公开(公告)日：2004-09-02

    申请号：DE50103029

    申请日：2001-09-11

    Applicant: BASF AG

    Inventor： HASSELWANDER OLIVER ,  KRAEMER KLAUS ,  BALDENIUS KAI-UWE ,  KLATT JOCHEN ,  SCHWEIKERT LONI

    IPC: A61K31/381 ,  A23L1/30 ,  A61K31/00 ,  A61K31/202 ,  A61K31/385 ,  A61P3/10 ,  A61P9/10 ,  A61P13/12 ,  A61P25/02 ,  A61P27/02

    Abstract: The present invention relates to the use of lipoic acid, a physiologically acceptable derivative or salt thereof and one compound of the formula I H3C-(CH2)n1-(CH=CH)n3-(CH2)n2-COOH I in which n1, n2 have, independently of one another, the value of an integer from 3 to 9, n3 has the value of an integer from 2 to 6, and the number of carbon atoms is 18, 20 or 22, a physiologically acceptable derivative or salt thereof, for nutritional supplementation, in functional foods and for therapeutic purposes in the treatment of diabetic disorders. Compositions having a corresponding active ingredient combination, and compositions in the form of commercial packs with corresponding combination products or single-drug products for combined use are also described.

Patent Agency Ranking